With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.15529-49-4,Dichlorotris(triphenylphosphino)ruthenium (II),as a common compound, the synthetic route is as follows.
Step 4: (PPh^2CI2Ru(3-2-methylphenyl-5-methylphenyl-inden-1 -ylidene) (1 D): (PPh3)3RuCl2 (1 eq., 0.575 g, 0.6 mmol) and 1 ,1 -bis-2-methylphenyl-prop-2-yn-1-ol (compound C, 1.5 eq., 0.213 g, 0.9 mmol) were added in 4 ml HCI/dioxane solution (0.15 mol/l). The solution was heated to 90C for 3 hour, after which the solvent was removed under vacuum. Hexane (20 ml) was added to the flask and the solid was ultrasonically removed from the wall. The resulting suspension was filtered and washed two times using hexane (5 ml). The remaining solvent was evaporated affording a red-brown powder; 0.52 g (Yield: 95 %). The product was characterized by NMR spectra H and 3 P. H NMR (300 MHz, CDCI3, TMS): delta 7.56 (dd, 1 1 H), 7.37 (t, 6 H), 7.21 -7.31 (m, 13 H), 7.09 (tetra, 3 H), 6.95 (t, 3 H), 6.47 (t, 1 H), 6.14 (s, 1 H), 2.20 (s, 3 H), 1 .66 (s, 3 H). 3 P NMR (121.49 MHz, CDCI3): delta 29.33.
As the paragraph descriping shows that 15529-49-4 is playing an increasingly important role.
Reference£º
Patent; GUANG MING INNOVATION COMPANY (WUHAN); W.C. VERPOORT, Francis; (69 pag.)WO2016/242; (2016); A1;,
Highly efficient and robust molecular ruthenium catalysts for water oxidation
Catalysts | Special Issue : Ruthenium Catalysts – MDPI